Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, U.S.A.
Winship Cancer Institute of Emory University, Atlanta, Georgia, U.S.A.
Laryngoscope. 2021 Feb;131(2):E466-E472. doi: 10.1002/lary.28725. Epub 2020 May 27.
To examine survival endpoints in patients with tumor (T)4b oral cavity squamous cell carcinoma (OCSCC) with pathologically proven masticator space invasion treated with primary surgery followed by adjuvant therapy.
Retrospective review at an academic cancer center.
Twenty-five patients with T4b OCSCC with pathologic masticator space invasion were treated with primary surgery from May 2012 to December 2016. Only patients with ≥ 2 years follow-up from date of surgery were included. Sixteen patients received adjuvant chemoradiation.
Median follow-up time was 39 months from date of surgery. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival at 24 months were 44.0%, 63.2%, and 52.6%, respectively. On univariate analyses, adjuvant chemoradiation was associated with improved OS. Advanced age and prolonged length of hospital stay was associated with worse OS.
For pT4b OCSCCA involving the masticator space, primary surgical resection followed by adjuvant chemoradiation demonstrates 24-month DSS of > 50% and OS of 44%.
4 Laryngoscope, 131:E466-E472, 2021.
研究经病理证实存在咀嚼肌间隙侵犯的 T4b 口腔鳞状细胞癌（OCSCC）患者的生存终点，这些患者接受了以手术为主的辅助治疗。
在学术癌症中心进行的回顾性研究。
2012 年 5 月至 2016 年 12 月，对 25 例经病理证实存在咀嚼肌间隙侵犯的 T4b OCSCC 患者进行了手术治疗。仅纳入从手术日期起随访时间≥2 年的患者。16 例患者接受了辅助放化疗。
手术日期后的中位随访时间为 39 个月。24 个月时的总体生存率（OS）、疾病特异性生存率（DSS）和无复发生存率分别为 44.0%、63.2%和 52.6%。单因素分析显示，辅助放化疗与 OS 改善相关。高龄和住院时间延长与 OS 较差相关。
对于累及咀嚼肌间隙的 pT4b OCSCCA，以手术为主的辅助放化疗可使 24 个月的 DSS ＞50%，OS 为 44%。
4 级，《喉镜》，131：E466-E472，2021。
